Haisco：HSK46256 has received its first clinical trial approval.
MSD：ENFLONSIA™Clesrovimab approved for marketing in China.
MSD：WINREVAIR™Sotatercept received marketing approval
CSPC：Cosentyx®Secukinumab Injection marketing application submitted
UCB：Galvokimig was approved
Roche：Lunsumio VELO™Mosunetuzumab marketing application submitted
Ocumension：NCX 470 is planned to be submitted for marketing approval.
Kerui：DN022150 has initiated a Phase III clinical trial.
Henlius：HLX3902 has received its clinical trial approval.
Juncell：GC101 is expected to be submitted for marketing approval in September.
